Public Hearing on the Pharmaceutical Legislation in Europe

July 2025

Shades of colour with EU building and Pulic hearing text with date and location

The Intergroup on Cancer and Rare Diseases will hold a high-level public hearing at the European Parliament to examine the ongoing reform of the EU’s pharmaceutical legislation. This pivotal event comes at a crucial moment in the legislative process and seeks to influence the final direction of the reform in favour of patients living with cancer, rare, and paediatric diseases.

💬 Public Hearing: EU’s pharmaceutical legislation reform, room N3.1
🗓️ Date: 10 July 2025
📍 Location: Strasbourg
⏰ 10:30 – 12:00 CET

The hearing will be co-chaired by five Members of the European Parliament (MEPs), representing a cross-party coalition dedicated to patient advocacy:

Tomislav Sokol (EPP, HR)
Vlad Voiculescu (Renew Europe, RO)
Tilly Metz (Greens/EFA, LU)
Stine Bosse (Renew Europe, DK)
Alessandra Moretti (S&D, IT)

The agenda will focus on how the revised pharmaceutical framework can:

Improve equitable access to innovation, ensuring that breakthrough therapies reach patients in urgent need;
Bolster incentives for currently underserved or neglected populations;
Place patients’ needs and lived experiences at the heart of EU health policy, promoting participatory governance and better-informed decisions.

This public hearing offers a timely forum for multi-stakeholder dialogue, as the Parliament prepares its position for the final stage of the Revision of the General Pharmaceutical Legislation. Among the key themes under discussion are:

Modulation of regulatory incentives to better address unmet needs;
The “first-in-child” approach to accelerate paediatric drug development;
Treatment optimisation strategies for improved outcomes;
Valuing patients’ expertise and promoting inclusive participation in research and policy development.

Stakeholders from across the health ecosystem—including patient organisations, academic experts, health insurers, and EU regulatory authorities—are expected to participate, bringing diverse perspectives to the debate. The hearing will include contributions from leading organisations and create space for meaningful exchanges aimed at shaping trilogue negotiations.

Attendance is open to the public. While no prior registration is required, please note that an accredited access badge to the European Parliament is necessary to enter the venue.

The hearing is also available via livestream at this link.